AXSM FY2025 EPS Forecast Lifted by Cantor Fitzgerald

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities researchers at Cantor Fitzgerald raised their FY2025 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Thursday, May 1st. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of ($4.02) per share for the year, up from their prior estimate of ($4.15). Cantor Fitzgerald currently has a "Overweight" rating and a $153.00 price target on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The company had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million.

Other equities research analysts have also recently issued reports about the company. Truist Financial lifted their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. Mizuho upped their price objective on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a report on Thursday, March 27th. William Blair reissued an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Axsome Therapeutics in a research note on Tuesday, February 11th. They set a "buy" rating and a $176.00 price target on the stock. Finally, Royal Bank of Canada lifted their price objective on shares of Axsome Therapeutics from $190.00 to $193.00 and gave the stock an "outperform" rating in a research note on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $170.33.

Axsome Therapeutics Price Performance

NASDAQ AXSM traded down $4.33 on Monday, reaching $112.16. The company had a trading volume of 716,105 shares, compared to its average volume of 685,724. The firm's 50 day moving average price is $113.35 and its 200 day moving average price is $104.18. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $139.13. The stock has a market capitalization of $5.52 billion, a PE ratio of -18.72 and a beta of 0.46. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22.

Hedge Funds Weigh In On Axsome Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Barclays PLC grew its holdings in Axsome Therapeutics by 279.6% during the 3rd quarter. Barclays PLC now owns 61,785 shares of the company's stock worth $5,552,000 after acquiring an additional 45,509 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Axsome Therapeutics by 47.5% during the third quarter. Franklin Resources Inc. now owns 160,534 shares of the company's stock valued at $13,713,000 after purchasing an additional 51,696 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Axsome Therapeutics by 14.9% during the third quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock valued at $19,062,000 after buying an additional 27,534 shares during the period. Pallas Capital Advisors LLC purchased a new position in Axsome Therapeutics during the fourth quarter valued at approximately $2,237,000. Finally, Flower City Capital bought a new position in Axsome Therapeutics in the fourth quarter worth approximately $254,000. Institutional investors own 81.49% of the company's stock.

Insider Activity

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the firm's stock in a transaction on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 22.40% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.